Tisbury Pharmaceuticals Launches with a USD 32 Million Series A...

Investment proceeds to be used to develop Tisbury's proprietary glaucoma compound, R-801(PRWeb June 14, 2017)Read the full story at http://www.prweb.com/releases/2017/06/prweb14418503.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news